Clinical Testing is Congruent with In Vitro Findings

Controlled in vivo trials are an important means of confirming the validity and application of laboratory testing. Randomized controlled clinical trials with additional toxicity measurements have confirmed these effects.

Research by Klukowska and colleagues incorporated subgingival plaque sampling in sites up to 4 mm in depth in a 4-week randomized controlled clinical trial of twice daily unsupervised brushing with a 0.454% bioavailable SnF2 dentifrice, wherein both a low gingival bleeding cohort (‘healthy’) and a high bleeding cohort (‘diseased’) were evaluated.35 Clinical effectiveness trials of marketed dentifrices do not commonly include subgingival plaque sampling, but its inclusion in this trial provided insight into the depths of penetration of SnF2, its retention, and its ability to reduce subgingival plaque toxicity. At Week 4, both cohorts saw significant (42% to 53%) mean reductions in gingival bleeding. The plaque sampling results in both the healthy and diseased groups provided evidence following use of SnF2 of notably decreased LPS/LTA dye activity and TLR activity. Morning wake-up plaque samples via salivary lavage showed significantly suppressed short-chain carboxylic acid toxins for both the low and high bleeding groups as well, suggesting robust substantivity.35,36

The researchers noted the important implication of this research and a previous complementary trial:37 The effects of SnF2 to bind with endotoxins and thereby limit TLR4/TLR2 in initiating the inflammatory cascade manifested both in the diseased, high bleeding sites and also in the low bleeding sites with minimal measurable disease, suggesting a preventive as well as a treatment gingivitis strategy.

A subsequent clinical trial evaluating SnF2 penetration within the sulcus and retention in gingival crevicular fluid (GCF) provided further evidence that SnF2 can influence the pathogenicity of microflora subgingivally.38 In this 2-week trial of subjects with a minimum of twenty bleeding dental pockets up to 4mm in depth and no recent SnF2 exposure, GCF samples were analyzed by mass spectrometry for the presence of tin (a stannous fluoride marker) at both 30 minutes and 12 hours after brushing with a bioavailable SnF2 dentifrice on Day 1. The results showed that significant (P<0.0001) levels of tin compared with baseline were detected in the GCF samples. Higher tin levels were seen at Day 14 after 2 weeks of home dentifrice use, suggesting an incremental effect with ongoing use.

More confirmation of bioavailable SnF2’s ability to diminish the virulence of subgingival plaque – and thus the development of gingivitis – was demonstrated by recent clinical research evaluating gingival inflammation and bleeding in 99 adult subjects with gingivitis.39 After 8 weeks of at-home 0.454% SnF2 dentifrice use, significant reductions in gingivitis and bleeding versus baseline were observed. These clinical observations were consistent with the results of subgingival plaque sampling, where TLR2 assay analyses of hTLR2 reporter gene activity showed significant (P=0.0004) mean reductions following two months of SnF2 brushing (Figure 9).

Figure 9.
Chart showing clinical observations were consistent with the results of subgingival plaque sampling, where TLR2 assay analyses of hTLR2 reporter gene activity showed significant (P=0.0004) mean reductions following two months of SnF2 brushing
An 8-week clinical trial of 99 subjects with pre-existing disease showed significant reductions in bleeding and gingivitis with bioavailable SnF2, consistent with significant reductions in hTLR2 reporter gene activity via subgingival plaque sampling.39

Incorporating SnF2 in a dentifrice to yield maximum esthetics and efficacy – including full bioavailability – mandates precise, well-skilled formulation.40,41 In recent years, several technological advances resulting from ongoing scientific innovations and testing have led to bioavailable SnF2 formulations which have provided superior tartar control and whitening benefits, along with the therapeutic benefits, versus a variety of dentifrice controls in multiple clinical trials. The extensive clinical research program by Procter & Gamble on SnF2 dentifrice, which has spanned numerous decades, resulted in a Crest dentifrice being the first to be recognized for seven attributes applicable to toothpastes in the American Dental Association Seal of Acceptance program:

  • Prevent or reduce enamel erosion
  • Prevent cavities
  • Prevent and reduce plaque
  • Prevent and reduce gingivitis
  • Reduce tooth sensitivity
  • Reduce bad breath
  • Remove tooth surface stain.42

Most recently, a novel SnF2 formulation (Crest Pro-Health Advanced Gum Restore) has been introduced with the amino acid glycine as a stabilizer for SnF2. This formulation, which has the American Dental Association Seal of Acceptance, promotes deeper penetration into the biofilm and improved retention of SnF2 within the plaque biofilm relative to SnF2 formulations without the glycine chelant. In vitro research shows the novel SnF2 dentifrice provides increased biofilm penetration and LPS neutralization efficacy, along with enhancing gingival cell recovery in a simulated wound healing model.43

The benefits have been demonstrated in clinical research. In one randomized clinical trial, the novel SnF2 dentifrice demonstrated significantly greater plaque reduction than a negative control and significantly greater tin retention subgingivally than a positive control SnF2 dentifrice.44 In a separate 12-week clinical trial, the novel SnF2 dentifrice produced statistically significant gingival bleeding reductions versus the negative control as soon as one week, demonstrating rapid activity. At Week 12, subjects using the SnF2 dentifrice had 33.4% fewer bleeding sites and 6 times greater odds of transitioning from localized or generalized gingivitis (>10% bleeding sites) to generally healthy (<10% bleeding sites) versus the negative control.45 chat Let's get started!